{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:40:16Z","timestamp":1760244016979,"version":"build-2065373602"},"reference-count":10,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2010,12,17]],"date-time":"2010-12-17T00:00:00Z","timestamp":1292544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The recent review of Matthew D. Krasowski on \u2018Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications\u2019 is a useful foundation of comparative interpretations on our current knowledge about therapeutic drug monitoring. Within the review, the statement that therapeutic drug monitoring has a minimal role in the therapeutic use of eslicarbazepine acetate due to its relatively predictable pharmacokinetics reflects the existing body of evidence although some information such as eslicarbazepine acetate\u2019s chemical structure, proportions of its metabolites, their pharmacokinetics and chiral method of plasma level measurement need to be revised. These critical characteristics differentiate the novel compound from former dibenzazepines such as carbamazepine and oxcarbazepine in its clinical effects and needs for therapeutic drug monitoring.<\/jats:p>","DOI":"10.3390\/ph3123629","type":"journal-article","created":{"date-parts":[[2010,12,17]],"date-time":"2010-12-17T11:57:53Z","timestamp":1292587073000},"page":"3629-3632","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comments on the Eslicarbazepine Acetate Section of the Article \u2018Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications\u2019"],"prefix":"10.3390","volume":"3","author":[{"given":"Ahmet H.","family":"\u00d6ztiryaki","sequence":"first","affiliation":[{"name":"BIAL - Portela & Ca, S.A., S. Mamede do Coronado, Portugal"}]},{"given":"Patricio","family":"Soares-da-Silva","sequence":"additional","affiliation":[{"name":"BIAL - Portela & Ca, S.A., S. Mamede do Coronado, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2010,12,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3390\/ph3061909","article-title":"Therapeutic drug monitoring of the newer anti-epilepsy medications","volume":"3","author":"Krasowski","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.nurt.2006.10.005","article-title":"Eslicarbazepine acetate (BIA 2-093)","volume":"4","author":"Almeida","year":"2007","journal-title":"Neurotherapeutics"},{"key":"ref_3","unstructured":"Zebinix\u00ae (Eslicarbazepine acetate) Summary of Product Characteristics. Available online:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000988\/WC500047225.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Shorvon, S., Perucca, E., and Engel, J. (2009). The Treatment of Epilepsy, Wiley-Blackwell. [3rd].","DOI":"10.1002\/9781444316667"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00228-007-0414-1","article-title":"Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment","volume":"64","author":"Almeida","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-0404.1992.tb05051.x","article-title":"Absence of interaction between oxcarbazepine and erythromycine","volume":"86","author":"Jolkklonen","year":"1992","journal-title":"Acta Neurol. Scand."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/bmc.858","article-title":"Simultaneous and enantioselective liquid chromatographic determination of eslicarbazepine acetate, S-licarbazepine, R-licarbazepine and oxcarbazepine in mouse tissue samples using ultraviolet detection","volume":"21","author":"Alves","year":"2007","journal-title":"Biomed. Chromatogr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1177\/0091270004267591","article-title":"Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans","volume":"44","author":"Almeida","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1177\/0091270005279364","article-title":"Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects","volume":"45","author":"Almeida","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/bdd.549","article-title":"Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker","volume":"28","author":"Maia","year":"2007","journal-title":"Biopharm. Drug Dispos."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/3\/12\/3629\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:04:08Z","timestamp":1760220248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/3\/12\/3629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,17]]},"references-count":10,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2010,12]]}},"alternative-id":["ph3123629"],"URL":"https:\/\/doi.org\/10.3390\/ph3123629","relation":{},"ISSN":["1424-8247"],"issn-type":[{"type":"electronic","value":"1424-8247"}],"subject":[],"published":{"date-parts":[[2010,12,17]]}}}